Intraoperative ketamine for reduction in postpartum depressive symptoms after cesarean delivery: A double‐blind, randomized clinical trial DOI Creative Commons
Jiaxin Yao, Tingting Song, Yue Zhang

et al.

Brain and Behavior, Journal Year: 2020, Volume and Issue: 10(9)

Published: Aug. 18, 2020

Abstract Background Postpartum depression (PPD) is a common mental disease happens in perinatal period. Ketamine as an anesthesia and analgesia drug has been used for long time. In recent years, ketamine proved to have antidepression effect with single administration. We hypothesized that intraoperative can reduce postpartum depressive symptoms after cesarean delivery. Methods randomized, double‐blind, placebo‐controlled study trail, healthy women scheduled delivery were randomly assigned receive intravenous (0.25 mg/kg diluted 5 ml 0.9% saline) or placebo (5 of within min following clamping the neonatal umbilical cord. The primary outcome was degree symptoms, which evaluated by Edinburgh Postnatal Depression Scale (EPDS, threshold 9/10 used) at 1 week, 2 weeks, month secondary numerical rating scale (NRS) score pain days postpartum. This trail registered Chinese Clinical Trial Registry, number ChiCTR1900022464. Results Between 26 January 2019 15 July 2019, 502 subjects screened 330 allocated: 165 (50%) group group. There significant differences between week (13.1% vs. 22.6%, respectively; p = .029). However, no difference found two groups weeks (11.8% 16.8%, .209) (10.5% 14.2%, .319). NRS wound (3.0 ± 0.9 4.0 1.0, < .001) uterine contraction 4.1 0.9, lower compared prevalence headache, hallucination, dizziness higher than during operation. Conclusions Operative mg/kg) week. long‐time remained be seen.

Language: Английский

Neuroactive Steroids, Toll-like Receptors, and Neuroimmune Regulation: Insights into Their Impact on Neuropsychiatric Disorders DOI Creative Commons
Irina Balan, Giorgia Boero, Samantha Lucenell Chéry

et al.

Life, Journal Year: 2024, Volume and Issue: 14(5), P. 582 - 582

Published: April 30, 2024

Pregnane neuroactive steroids, notably allopregnanolone and pregnenolone, exhibit efficacy in mitigating inflammatory signals triggered by toll-like receptor (TLR) activation, thus attenuating the production of factors. Clinical studies highlight their therapeutic potential, particularly conditions like postpartum depression (PPD), where FDA-approved compound brexanolone, an intravenous formulation allopregnanolone, effectively suppresses TLR-mediated pathways, predicting symptom improvement. Additionally, pregnane neurosteroids trophic anti-inflammatory properties, stimulating vital proteins Androstane including estrogens androgens, along with dehydroepiandrosterone (DHEA), display diverse effects on TLR expression activation. Notably, androstenediol (ADIOL), androstane neurosteroid, emerges as a potent agent, promising for interventions. The dysregulation immune responses via signaling alongside reduced levels endogenous significantly contributes to severity across various neuropsychiatric disorders. Neuroactive such demonstrate alleviating symptoms disorders modulating neuroimmune responses, offering potential intervention avenues. This review emphasizes significant steroids addressing processes associated It advances our understanding complex interplay between paving way personalized treatment strategies tailored individual needs providing insights future research aimed at unraveling intricacies

Language: Английский

Citations

8
Attention-Deficit Hyperactivity Disorder (ADHD) Medication Use Trajectories Among Women in the Perinatal Period DOI Creative Commons
Kathrine Bang Madsen, Mette Bliddal, Charlotte Skoglund

et al.

CNS Drugs, Journal Year: 2024, Volume and Issue: 38(4), P. 303 - 314

Published: March 15, 2024

An increasing number of women reproductive age are treated with attention-deficit hyperactivity disorder (ADHD) medication; however, patterns ADHD medication use for in the perinatal period have not been well described. This study aimed to describe from 1 year before pregnancy after delivery, and sociodemographic characteristics clinical features by trajectories. The population-based cohort included pregnancies Denmark between 1997 2020, Medical Birth Register, who filled at least one prescription 12 months until delivery. We applied group-based trajectory modeling classify into subgroups based on identification heterogeneous treatment patterns, described associated these groups. Overall, we 4717 leading liveborn singletons 4052 mothers a mean (standard deviation) 27.5 (5.6) years. identified four trajectories across postpartum period: continuers (23.3%), discontinuers (41.8%), interrupters ceased filling prescriptions during but resumed (17.2%), initiators (17.7%). Continuers were older time conception, gave birth more recent years, likely smoke pregnancy, used other psychotropic medications pregnancy. A large proportion methylphenidate (89.1%) compared groups (75.9–84.1%) had switched type whole (16.4% vs. 7.4–14.8%). found that approximately 60% discontinued or interrupted their around those continued differed factors may reflect severe ADHD.

Language: Английский

Citations

7
Depression Treatment in Pregnancy: Is It Safe, or Is It Not? DOI Open Access
Vitalba Gallitelli,

Rita Franco,

Sofia Guidi

et al.

International Journal of Environmental Research and Public Health, Journal Year: 2024, Volume and Issue: 21(4), P. 404 - 404

Published: March 26, 2024

Prenatal depression carries substantial risks for maternal and fetal health increases susceptibility to postpartum depression. Untreated in pregnancy is correlated with adverse outcomes such as an increased risk of suicidal ideation, miscarriage neonatal growth problems. Notwithstanding concerns about the use antidepressants, available treatment options emphasize importance specialized medical supervision during gestation. The purpose this paper conduct a brief literature review on main antidepressant drugs their effects pregnancy, assessing benefits. analysis shows that it essential be followed by doctors multidisciplinary teams (obstetricians, psychiatrists psychologists) who attend woman’s needs. Depression can now treated safely choosing have no teratogenic fewer side both mother child. Comprehensive strategies involving awareness, early diagnosis, clear guidelines effective are mitigate impact perinatal

Language: Английский

Citations

6
Pregnancy, postpartum and parity: Resilience and vulnerability in brain health and disease DOI

Nicholas P. Deems,

Benedetta Leuner

Frontiers in Neuroendocrinology, Journal Year: 2020, Volume and Issue: 57, P. 100820 - 100820

Published: Jan. 24, 2020

Language: Английский

Citations

48
Intraoperative ketamine for reduction in postpartum depressive symptoms after cesarean delivery: A double‐blind, randomized clinical trial DOI Creative Commons
Jiaxin Yao, Tingting Song, Yue Zhang

et al.

Brain and Behavior, Journal Year: 2020, Volume and Issue: 10(9)

Published: Aug. 18, 2020

Abstract Background Postpartum depression (PPD) is a common mental disease happens in perinatal period. Ketamine as an anesthesia and analgesia drug has been used for long time. In recent years, ketamine proved to have antidepression effect with single administration. We hypothesized that intraoperative can reduce postpartum depressive symptoms after cesarean delivery. Methods randomized, double‐blind, placebo‐controlled study trail, healthy women scheduled delivery were randomly assigned receive intravenous (0.25 mg/kg diluted 5 ml 0.9% saline) or placebo (5 of within min following clamping the neonatal umbilical cord. The primary outcome was degree symptoms, which evaluated by Edinburgh Postnatal Depression Scale (EPDS, threshold 9/10 used) at 1 week, 2 weeks, month secondary numerical rating scale (NRS) score pain days postpartum. This trail registered Chinese Clinical Trial Registry, number ChiCTR1900022464. Results Between 26 January 2019 15 July 2019, 502 subjects screened 330 allocated: 165 (50%) group group. There significant differences between week (13.1% vs. 22.6%, respectively; p = .029). However, no difference found two groups weeks (11.8% 16.8%, .209) (10.5% 14.2%, .319). NRS wound (3.0 ± 0.9 4.0 1.0, < .001) uterine contraction 4.1 0.9, lower compared prevalence headache, hallucination, dizziness higher than during operation. Conclusions Operative mg/kg) week. long‐time remained be seen.

Language: Английский

Citations

48